Janux Therapeutics (JANX) Competitors $24.30 +0.30 (+1.25%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$24.12 -0.18 (-0.72%) As of 08/22/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. RNA, NUVL, AXSM, CRSP, ABVX, MRUS, CYTK, VKTX, TGTX, and KRYSShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Avidity Biosciences (RNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Abivax (ABVX), Merus (MRUS), Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Its Competitors Avidity Biosciences Nuvalent Axsome Therapeutics CRISPR Therapeutics Abivax Merus Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech Janux Therapeutics (NASDAQ:JANX) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership. Does the media favor JANX or RNA? In the previous week, Avidity Biosciences had 10 more articles in the media than Janux Therapeutics. MarketBeat recorded 15 mentions for Avidity Biosciences and 5 mentions for Janux Therapeutics. Avidity Biosciences' average media sentiment score of 1.05 beat Janux Therapeutics' score of 0.70 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, JANX or RNA? Janux Therapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Do insiders and institutionals hold more shares of JANX or RNA? 75.4% of Janux Therapeutics shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, JANX or RNA? Janux Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. Janux Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10.59M137.88-$68.99M-$1.80-13.50Avidity Biosciences$10.90M547.06-$322.30M-$3.56-13.02 Do analysts prefer JANX or RNA? Janux Therapeutics currently has a consensus target price of $86.90, indicating a potential upside of 257.61%. Avidity Biosciences has a consensus target price of $67.00, indicating a potential upside of 44.55%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Janux Therapeutics is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.06 Is JANX or RNA more profitable? Janux Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -4,247.77%. Janux Therapeutics' return on equity of -11.48% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -11.48% -11.01% Avidity Biosciences -4,247.77%-33.45%-30.22% SummaryJanux Therapeutics beats Avidity Biosciences on 11 of the 17 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.46B$3.12B$5.83B$9.78BDividend YieldN/A2.23%4.40%4.05%P/E Ratio-13.5021.0031.3026.05Price / Sales137.88357.30455.25117.77Price / CashN/A44.5038.0259.36Price / Book1.478.129.536.60Net Income-$68.99M-$54.72M$3.26B$265.65M7 Day Performance-3.23%2.62%2.14%2.01%1 Month Performance-8.16%2.68%2.81%-0.33%1 Year Performance-47.08%10.93%30.70%19.04% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics2.0629 of 5 stars$24.30+1.3%$86.90+257.6%-45.0%$1.46B$10.59M-13.5030News CoverageRNAAvidity Biosciences3.1767 of 5 stars$44.48-4.3%$67.00+50.6%+8.2%$5.98B$10.90M-12.49190Positive NewsInsider TradeOptions VolumeNUVLNuvalent3.3897 of 5 stars$75.01-1.4%$119.60+59.4%-8.3%$5.48BN/A-15.3140News CoverageAnalyst ForecastInsider TradeAXSMAxsome Therapeutics4.7994 of 5 stars$111.13+1.8%$178.00+60.2%+36.0%$5.45B$385.69M-21.92380News CoveragePositive NewsCRSPCRISPR Therapeutics3.7823 of 5 stars$57.59-3.6%$71.60+24.3%+14.4%$5.43B$37.31M-10.61460Positive NewsABVXAbivax2.9061 of 5 stars$70.01-0.6%$92.33+31.9%+562.8%$5.32BN/A0.0061Positive NewsShort Interest ↑MRUSMerus2.3111 of 5 stars$66.00-1.9%$88.50+34.1%+26.5%$5.09B$36.13M-12.0037News CoveragePositive NewsCYTKCytokinetics3.7202 of 5 stars$38.95+0.7%$71.58+83.8%-31.8%$4.63B$18.47M-7.64250News CoverageVKTXViking Therapeutics3.9956 of 5 stars$42.09+5.1%$86.92+106.5%-59.6%$4.50BN/A-27.5120Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3409 of 5 stars$27.73-1.2%$46.25+66.8%+20.7%$4.46B$329M74.95290Positive NewsKRYSKrystal Biotech4.7224 of 5 stars$146.30-2.6%$210.75+44.1%-23.8%$4.35B$290.52M29.74210Trending NewsAnalyst Forecast Related Companies and Tools Related Companies RNA Competitors NUVL Competitors AXSM Competitors CRSP Competitors ABVX Competitors MRUS Competitors CYTK Competitors VKTX Competitors TGTX Competitors KRYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access